Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole

Posaconazole: A new oral antifungal agent with an expanded spectrum of activity

(2009) Michele I. Morris   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents

(2009) Naveen Kumar Chennamaneni et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Dynamics ofin vitro acquisition of resistance byCandida parapsilosisto different azoles

(2009) Ana Teresa Pinto e Silva et al.   FEMS YEAST RESEARCH

Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Structurally Simple Inhibitors of Lanosterol 14α-Demethylase Are Efficacious In a Rodent Model of Acute Chagas Disease

(2009) Praveen Kumar Suryadevara et al.   JOURNAL OF MEDICINAL CHEMISTRY

Two approaches to discovering and developing new drugs for Chagas disease

(2009) JH McKerrow et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit

(2009) Chiung-Kuang Chen et al.   PLoS Neglected Tropical Diseases

Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus

(2008) J. L. Rodriguez-Tudela et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

X-ray Structure of 4,4′-Dihydroxybenzophenone Mimicking Sterol Substrate in the Active Site of Sterol 14α-Demethylase (CYP51)

(2008) Ali Nasser Eddine et al.   JOURNAL OF BIOLOGICAL CHEMISTRY